1
|
Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perréard M, Abeilard E, Giffard F, Brotin E, Denoyelle C, Villenet C, Sebda S, Briand M, Joly F, Dolivet E, Goux D, Blanc-Fournier C, Jeanne C, Villedieu M, Meryet-Figuiere M, Figeac M, Poulain L, Weiswald LB. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. J Exp Clin Cancer Res 2023; 42:260. [PMID: 37803448 PMCID: PMC10559504 DOI: 10.1186/s13046-023-02809-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 08/22/2023] [Indexed: 10/08/2023] Open
Abstract
BACKGROUND In the era of personalized medicine, the establishment of preclinical models of cancer that faithfully recapitulate original tumors is essential to potentially guide clinical decisions. METHODS We established 7 models [4 cell lines, 2 Patient-Derived Tumor Organoids (PDTO) and 1 Patient-Derived Xenograft (PDX)], all derived from the same Ovarian Clear Cell Carcinoma (OCCC). To determine the relevance of each of these models, comprehensive characterization was performed based on morphological, histological, and transcriptomic analyses as well as on the evaluation of their response to the treatments received by the patient. These results were compared to the clinical data. RESULTS Only the PDX and PDTO models derived from the patient tumor were able to recapitulate the patient tumor heterogeneity. The patient was refractory to carboplatin, doxorubicin and gemcitabine, while tumor cell lines were sensitive to these treatments. In contrast, PDX and PDTO models displayed resistance to the 3 drugs. The transcriptomic analysis was consistent with these results since the models recapitulating faithfully the clinical response grouped together away from the other classical 2D cell culture models. We next investigated the potential of drugs that have not been used in the patient clinical management and we identified the HDAC inhibitor belinostat as a potential effective treatment based on PDTO response. CONCLUSIONS PDX and PDTO appear to be the most relevant models, but only PDTO seem to present all the necessary prerequisites for predictive purposes and could constitute relevant tools for therapeutic decision support in the context of these particularly aggressive cancers refractory to conventional treatments.
Collapse
Affiliation(s)
- Lucie Thorel
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
| | - Pierre-Marie Morice
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
| | - Hippolyte Paysant
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
| | - Romane Florent
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- Université de Caen Normandie, Services Unit PLATON, ORGAPRED Core Facility, Caen, France
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Guillaume Babin
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Department of Surgery, Caen, France
| | - Cécilia Thomine
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
| | - Marion Perréard
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
| | - Edwige Abeilard
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Florence Giffard
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Emilie Brotin
- Université de Caen Normandie, Services Unit PLATON, ImpedanCell Core Facility, Caen, France
| | - Christophe Denoyelle
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
- Université de Caen Normandie, Services Unit PLATON, ImpedanCell Core Facility, Caen, France
| | - Céline Villenet
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France
| | - Shéhérazade Sebda
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France
| | - Mélanie Briand
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Biological Resources Center 'OvaRessources', Caen, France
| | - Florence Joly
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Clinical Research Department, Caen, France
| | - Enora Dolivet
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Department of Surgery, Caen, France
| | - Didier Goux
- Université de Caen Normandie, Services Unit EMERODE, « Centre de Microscopie Appliquée À La Biologie » CMAbio3, Caen, France
| | - Cécile Blanc-Fournier
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Biological Resources Center 'OvaRessources', Caen, France
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Department of Biopathology, Caen, France
| | - Corinne Jeanne
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Department of Biopathology, Caen, France
| | - Marie Villedieu
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
| | - Matthieu Meryet-Figuiere
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France
| | - Martin Figeac
- University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France
| | - Laurent Poulain
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.
- Université de Caen Normandie, Services Unit PLATON, ORGAPRED Core Facility, Caen, France.
- UNICANCER, Comprehensive Cancer Center Francois Baclesse, Biological Resources Center 'OvaRessources', Caen, France.
| | - Louis-Bastien Weiswald
- Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), 3 Avenue du Général Harris, BP 45026, 14 076, Caen, Cedex 05, France.
- Université de Caen Normandie, Services Unit PLATON, ORGAPRED Core Facility, Caen, France.
- UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.
| |
Collapse
|
2
|
Gobert D, Launay D, Boccon-Gibod I, De Moreuil C, Bourgoin-Heck M, Aubineau M, Debord-Peguet S, Jeandel P, Jaussaud R, Du-Thanh A, Armengol G, Hoarau C, Ollivier Y, Pontille F, Guez S, Villedieu M, Crave J, Fain O, Bouillet L. Efficacité et tolérance du bérotralstat dans la prévention des crises récurrentes d’angiœdème héréditaire : analyse intermédiaire de l’étude observationnelle en vie réelle « BEROLIFE ». Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
3
|
Duboc C, Abeilard E, Voisin-Chiret AS, Gauduchon P, Poulain L, Villedieu M. Abstract 1921: The sensitivity of ovarian cancer cells to the HDAC inhibitor belinostat is improved by inhibiting Bcl-xL or Mcl-1 anti-apoptotic proteins. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-1921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The identification of novel therapeutic strategies is an important urgent requirement for the clinical management of ovarian cancers, which remain the leading cause of death from gynecologic cancer. Our previous studies have shown that the anti-apoptotic proteins Bcl-xL and Mcl-1 cooperate to protect resistant ovarian cancer cells from apoptosis as their concomitant inhibition results in massive apoptotic cell death. Moreover, their BH3-only pro-apoptotic partners Bim and Puma are crucial actors in the induced cell death. This suggests that ovarian cancer cell apoptosis can be triggered by inhibiting Bcl-xL and Mcl-1 and/or by promoting their BH3-only partners, especially Bim and Puma. The expression of these Bcl-2 family proteins has been reported to be modulated by HDAC (histone deacetylases) inhibitors in various cancer models. The objective of the present study was to evaluate the efficacy of the FDA-approved pan-HDAC inhibitor belinostat (i) to reduce the [Bcl-xL and Mcl-1] / BH3-only proteins ratio and (ii) to trigger apoptosis in chemoresistant ovarian cancer cell lines, alone or in combination with other pharmacological molecules that modulate these Bcl-2 family proteins. HDAC inhibition by belinostat led to a G2/M blockade and consequently reduced cell proliferation. Moreover, belinostat used at high concentrations (from 1000 to 2000 nM) efficiently triggered apoptosis in chemoresistant ovarian cancer cells. This cytotoxic effect was associated with both an up-regulation of Bim and Puma protein expression and an inhibition of Bcl-xL protein expression. Used at sub-toxic concentrations, belinostat also up-regulated Bim and Puma proteins but failed to down-regulate Bcl-xL and Mcl-1 protein expression. We therefore investigated whether Bcl-xL or Mcl-1 inhibition could sensitize ovarian cancer cells to sub-toxic concentrations of belinostat. Interestingly, the combination of belinostat with the BH3-mimetic ABT-737, that inhibits Bcl-xL, induced massive apoptosis. Moreover, Mcl-1 direct or indirect inhibition was also very efficient to sensitize ovarian cancer cells to belinostat. These results suggest that belinostat, alone or in association with pharmacological molecules that inhibit Mcl-1 or Bcl-xL, represents a promising approach for the treatment of chemoresistant ovarian cancers.
Citation Format: Charlène Duboc, Edwige Abeilard, Anne Sophie Voisin-Chiret, Pascal Gauduchon, Laurent Poulain, Marie Villedieu. The sensitivity of ovarian cancer cells to the HDAC inhibitor belinostat is improved by inhibiting Bcl-xL or Mcl-1 anti-apoptotic proteins [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1921.
Collapse
Affiliation(s)
- Charlène Duboc
- 1Normandie University, UNICAEN, Inserm U1086 ANTICIPE, Comprehensive Cancer Center F. Baclesse, BioTICLA group, Caen, France
| | - Edwige Abeilard
- 1Normandie University, UNICAEN, Inserm U1086 ANTICIPE, Comprehensive Cancer Center F. Baclesse, BioTICLA group, Caen, France
| | | | - Pascal Gauduchon
- 1Normandie University, UNICAEN, Inserm U1086 ANTICIPE, Comprehensive Cancer Center F. Baclesse, BioTICLA group, Caen, France
| | - Laurent Poulain
- 1Normandie University, UNICAEN, Inserm U1086 ANTICIPE, Comprehensive Cancer Center F. Baclesse, BioTICLA group, Caen, France
| | - Marie Villedieu
- 1Normandie University, UNICAEN, Inserm U1086 ANTICIPE, Comprehensive Cancer Center F. Baclesse, BioTICLA group, Caen, France
| |
Collapse
|
4
|
Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737. Mol Cancer Ther 2016; 16:102-115. [DOI: 10.1158/1535-7163.mct-16-0342] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Revised: 10/24/2016] [Accepted: 11/06/2016] [Indexed: 11/16/2022]
|
5
|
Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res 2015; 17:13. [PMID: 25633049 PMCID: PMC4342894 DOI: 10.1186/s13058-015-0515-1] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Accepted: 01/08/2015] [Indexed: 12/14/2022] Open
Abstract
Introduction Increasing evidence indicates that microRNAs (miRNAs) are important players in oncogenesis. Considering the widespread use of aromatase inhibitors (AIs) in endocrine therapy as a first-line treatment for postmenopausal estrogen receptor α–positive breast cancer patients, identifying deregulated expression levels of miRNAs in association with AI resistance is of utmost importance. Methods To gain further insight into the molecular mechanisms underlying the AI resistance, we performed miRNA microarray experiments using a new model of acquired resistance to letrozole (Res-Let cells), obtained by long-term exposure of aromatase-overexpressing MCF-7 cells (MCF-7aro cells) to letrozole, and a model of acquired anastrozole resistance (Res-Ana cells). Three miRNAs (miR-125b, miR-205 and miR-424) similarly deregulated in both AI-resistant cell lines were then investigated in terms of their functional role in AI resistance development and breast cancer cell aggressiveness and their clinical relevance using a cohort of 65 primary breast tumor samples. Results We identified the deregulated expression of 33 miRNAs in Res-Let cells and of 18 miRNAs in Res-Ana cells compared with the sensitive MCF-7aro cell line. The top-ranked Kyoto Encyclopedia of Genes and Genomes pathways delineated by both miRNA signatures converged on the AKT/mTOR pathway, which was found to be constitutively activated in both AI-resistant cell lines. We report for the first time, to our knowledge, that ectopic overexpression of either miR-125b or miR-205, or the silencing of miR-424 expression, in the sensitive MCF-7aro cell line was sufficient to confer resistance to letrozole and anastrozole, to target and activate the AKT/mTOR pathway and to increase the formation capacity of stem-like and tumor-initiating cells possessing self-renewing properties. Increasing miR-125b expression levels was also sufficient to confer estrogen-independent growth properties to the sensitive MCF-7aro cell line. We also found that elevated miR-125b expression levels were a novel marker for poor prognosis in breast cancer and that targeting miR-125b in Res-Let cells overcame letrozole resistance. Conclusion This study highlights that acquisition of specific deregulated miRNAs is a newly discovered alternative mechanism developed by AI-resistant breast cancer cells to achieve constitutive activation of the AKT/mTOR pathway and to develop AI resistance. It also highlights that miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target in AI-resistant breast cancers. Electronic supplementary material The online version of this article (doi:10.1186/s13058-015-0515-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Paul Vilquin
- ISPB, Faculté de Pharmacie, 8 Avenue Rockefeller, 69008, Lyon, France. .,Université Lyon 1, 8 Avenue Rockefeller, 69008, Lyon, France. .,INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69008, Lyon, France.
| | - Caterina F Donini
- ISPB, Faculté de Pharmacie, 8 Avenue Rockefeller, 69008, Lyon, France. .,Université Lyon 1, 8 Avenue Rockefeller, 69008, Lyon, France. .,INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69008, Lyon, France. .,Unité Cancer et Environnement, Centre Léon Bérard-Université Lyon 1, 28 Rue Laennec, 69008, Lyon, France.
| | - Marie Villedieu
- ISPB, Faculté de Pharmacie, 8 Avenue Rockefeller, 69008, Lyon, France. .,Université Lyon 1, 8 Avenue Rockefeller, 69008, Lyon, France. .,INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69008, Lyon, France.
| | - Evelyne Grisard
- ISPB, Faculté de Pharmacie, 8 Avenue Rockefeller, 69008, Lyon, France. .,Université Lyon 1, 8 Avenue Rockefeller, 69008, Lyon, France. .,INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69008, Lyon, France.
| | - Laura Corbo
- Université Lyon 1, 8 Avenue Rockefeller, 69008, Lyon, France. .,INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69008, Lyon, France.
| | | | - Julie A Vendrell
- ISPB, Faculté de Pharmacie, 8 Avenue Rockefeller, 69008, Lyon, France. .,Université Lyon 1, 8 Avenue Rockefeller, 69008, Lyon, France. .,INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69008, Lyon, France.
| | - Pascale A Cohen
- ISPB, Faculté de Pharmacie, 8 Avenue Rockefeller, 69008, Lyon, France. .,Université Lyon 1, 8 Avenue Rockefeller, 69008, Lyon, France. .,INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69008, Lyon, France. .,Unité Cancer et Environnement, Centre Léon Bérard-Université Lyon 1, 28 Rue Laennec, 69008, Lyon, France. .,ProfileXpert, SFR Lyon-Est, 69008, Lyon, France. .,ISPBL-Faculté de Pharmacie de Lyon, 8 Avenue Rockefeller, 69373, Lyon, Cedex 08, France.
| |
Collapse
|
6
|
Jebahi A, Villedieu M, Pétigny C, Brotin E, Louis M, Abeilard E, Giffard F, Gauduchon P, Lheureux S, Poulain L. 849: PI3K/mTOR dual inhibition modulates Bcl-2 family proteins expression and sensitizes ovarian carcinoma cells to ABT-737. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50752-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. Cancer Lett 2014; 348:38-49. [PMID: 24650799 DOI: 10.1016/j.canlet.2014.03.001] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2013] [Revised: 02/10/2014] [Accepted: 03/04/2014] [Indexed: 01/25/2023]
Abstract
We previously showed that Bcl-xL and Mcl-1 cooperatively protect platinum-resistant ovarian cancer cells from apoptosis. Here we assessed the anticancer potential of combining ABT-737-induced inhibition of Bcl-xL with Mcl-1 inhibition via PI3K/Akt/mTOR pathway disruption using NVP-BEZ235. NVP-BEZ235 inhibited cell proliferation without inducing apoptosis. It strongly repressed Mcl-1 expression and induced Puma expression in both cell lines tested while differentially modulating Bim between the two. Interestingly, NVP-BEZ235 efficiently sensitized ovarian carcinoma cells to ABT-737, provided that Bim expression was induced. Moreover, inhibiting the ERK1/2 pathway restored Bim expression and sensitized low Bim-expressing cancer cells to the BEZ235/ABT-737 treatment.
Collapse
Affiliation(s)
- Abdelghani Jebahi
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Marie Villedieu
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France; (d)On secondment from ISPB, Faculte de Pharmacie, Universite Lyon 1, Lyon, France.
| | - Cécile Pétigny-Lechartier
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Emilie Brotin
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France
| | - Marie-Hélène Louis
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Edwige Abeilard
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Florence Giffard
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Marika Guercio
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France
| | - Mélanie Briand
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Pascal Gauduchon
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Stéphanie Lheureux
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France; Clinical Research Department, François Baclesse Comprehensive Cancer Centre, Caen, France; Oncologic Uro-Gynaecology Department, François Baclesse Comprehensive Cancer Centre, Caen, France
| | - Laurent Poulain
- Normandy University, France; UNICAEN, "Biology and Innovative Therapeutics of Locally Aggressive Cancers" Unit (EA 4656), Caen, France; François Baclesse Comprehensive Cancer Centre, Caen, France
| |
Collapse
|
8
|
Vilquin P, Villedieu M, Grisard E, Larbi SB, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA. Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence ofde novoor acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer 2013; 133:1589-602. [DOI: 10.1002/ijc.28182] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2012] [Accepted: 03/07/2013] [Indexed: 01/01/2023]
Affiliation(s)
| | | | | | | | - Sandra E. Ghayad
- INSERM U1052; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon; Lyon; France
| | | | | | - Laura Corbo
- INSERM U1052; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon; Lyon; France
| | | | | | | |
Collapse
|
9
|
Vilquin P, Villedieu M, Grisard E, Larbi SB, Ghayad S, Bachelot T, Corbo L, Treilleux I, Vendrell J, Cohen P. 989 Acquired Resistance to Aromatase Inhibitors is Paired With Hyper-activation of Akt/mTor Pathway in New Cellular Models of Hormone-dependent Breast Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71607-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
10
|
Thollet A, Vendrell JA, Payen L, Ghayad SE, Ben Larbi S, Grisard E, Collins C, Villedieu M, Cohen PA. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol Cancer 2010; 9:291. [PMID: 21059223 PMCID: PMC2996367 DOI: 10.1186/1476-4598-9-291] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2010] [Accepted: 11/08/2010] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND ZNF217 is a candidate oncogene located at 20q13, a chromosomal region frequently amplified in breast cancers. The precise mechanisms involved in ZNF217 pro-survival function are currently unknown, and utmost importance is given to deciphering the role of ZNF217 in cancer therapy response. RESULTS We provide evidence that stable overexpression of ZNF217 in MDA-MB-231 breast cancer cells conferred resistance to paclitaxel, stimulated cell proliferation in vitro associated with aberrant expression of several cyclins, and increased tumor growth in mouse xenograft models. Conversely, siRNA-mediated silencing of ZNF217 expression in MCF7 breast cancer cells, which possess high endogenous levels of ZNF217, led to decreased cell proliferation and increased sensitivity to paclitaxel. The paclitaxel resistance developed by ZNF217-overexpressing MDA-MB-231 cells was not mediated by the ABCB1/PgP transporter. However, ZNF217 was able to counteract the apoptotic signals mediated by paclitaxel as a consequence of alterations in the intrinsic apoptotic pathway through constitutive deregulation of the balance of Bcl-2 family proteins. Interestingly, ZNF217 expression levels were correlated with the oncogenic kinase Aurora-A expression levels, as ZNF217 overexpression led to increased expression of the Aurora-A protein, whereas ZNF217 silencing was associated with low Aurora-A expression levels. We showed that a potent Aurora-A kinase inhibitor was able to reverse paclitaxel resistance in the ZNF217-overexpressing cells. CONCLUSION Altogether, these data suggest that ZNF217 might play an important role in breast neoplastic progression and chemoresistance, and that Aurora-A might be involved in ZNF217-mediated effects.
Collapse
|
11
|
Thollet A, Vendrell J, Payen L, Ghayad S, Ben Larbi S, Collins C, Villedieu M, Cohen P. 674 ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71471-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
12
|
Aurélie T, Vendrell J, Payen L, Ghayad S, Ben Larbi S, Villedieu M, Cohen P. 113: ZNF-X conferred increased cell proliferation and resistance to the pro-apoptotic action of paclitaxel in breast cancer cells. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31206-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 2010; 126:885-95. [PMID: 19634140 DOI: 10.1002/ijc.24787] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In ovarian carcinomas, recurrence and acquired chemoresistance are the first leading causes of therapeutic failure and are responsible for the poor overall survival rate. Cisplatin exposure of sensitive cells has been previously associated with a down-regulation of Bcl-X(L) expression and apoptosis, whereas recurrence was systematically observed when Bcl-X(L) expression was maintained. Bcl-X(L) down-regulation could thus constitute an interesting chemosensitizing strategy. We showed that a Bcl-X(L)targeted RNA interference strategy efficiently sensitized chemoresistant ovarian carcinoma cells to cisplatin, but some of them were still able to re-proliferate. Considering the possible cooperation between Bcl-X(L)and MCL-1, we investigated the possibility to avoid recurrence in vitro using a multi-targeted RNAi strategy directed against these two anti-apoptotic proteins. We showed that their concomitant inhibition lead to massive apoptosis in absence of cisplatin, this multi-targeted RNAi approach being much more efficient than conventional chemotherapy. We thus demonstrated that Bcl-X(L) and MCL-1 cooperate to constitute together a strong molecular "bolt", which elimination could be sufficient to allow chemoresistant ovarian carcinoma cells apoptosis. Moreover, we demonstrated that in presence of a low concentration of cisplatin, the concomitant down-regulation of Bcl-X(L) and MCL-1 allowed a complete annihilation of tumour cells population thus avoiding subsequent recurrence in vitro in cell lines highly refractory to any type of conventional chemotherapy. Therefore, Bcl-X(L) and MCL-1 targeted strategies could constitute an efficient therapeutic tool for the treatment of chemoresistant ovarian carcinoma, in association with conventional chemotherapy.
Collapse
Affiliation(s)
- Emilie Brotin
- Groupe Régional d'Etudes sur le Cancer (EA 1772, Université de Caen), Unité Biologie et Thérapies Innovantes des Cancers Localement Agressifs, Centre de Lutte Contre le Cancer F. Baclesse, Caen, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells☆. Gynecol Oncol 2007; 105:31-44. [PMID: 17275076 DOI: 10.1016/j.ygyno.2006.12.011] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2006] [Revised: 11/28/2006] [Accepted: 12/05/2006] [Indexed: 11/15/2022]
Abstract
OBJECTIVE Recurrence and subsequent acquired chemoresistance to platinum-based treatments constitute major hurdles to ovarian carcinoma therapy. Our objective was to examine the involvement of Bcl-xL anti-apoptotic protein in resistance to cisplatin. METHODS We described the effect of cisplatin on cell cycle and apoptosis induction in sensitive (IGROV1 and OAW42) and resistant (IGROV1-R10 and SKOV3) ovarian carcinoma cell lines. We correlated it with Bcl-xL mRNA and protein expression after exposure to cisplatin. We then used bcl-xS gene transfer to impede Bcl-xL activity. RESULTS Our study showed that Bcl-xL basal expression was high in both sensitive and resistant cell lines, as well as in all the studied ovarian tumor samples. Thus, Bcl-xL basal expression could not allow to predict sensitivity. Wondering whether variation of Bcl-xL level in response to cisplatin could be a better determinant of sensitivity, we investigated the expression of this protein in the cell lines after treatment. Cisplatin-induced down-regulation of Bcl-xL was strictly associated with apoptosis and absence of recurrence in vitro. Conversely, the maintenance of Bcl-xL expression in response to cisplatin appeared as a sine qua non condition to escape to treatment. To try to sensitize SKOV3 cells by impeding anti-apoptotic activity of Bcl-xL, we transfected bcl-xS gene in these cells. Bcl-xS exogenous expression was only slightly cytotoxic on its own, but highly sensitized SKOV3 resistant cells to cisplatin-induced apoptosis, and delayed recurrence. CONCLUSION This work thus provides one more argument to put Bcl-xL forward as a pertinent target of inhibition to overcome chemoresistance of epithelial ovarian carcinoma.
Collapse
Affiliation(s)
- M Villedieu
- Groupe Régional d'Etudes sur le Cancer, Unité Biologie et Thérapies Innovantes des Cancers Localement Agressifs, Centre de Lutte Contre le Cancer François Baclesse, Avenue du général Harris, 14076 Caen cedex 05, France
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Villedieu M, Briand M, Duval M, Héron JF, Gauduchon P, Poulain L. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression. Gynecol Oncol 2007; 105:373-84. [PMID: 17276501 DOI: 10.1016/j.ygyno.2006.12.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2006] [Revised: 12/19/2006] [Accepted: 12/21/2006] [Indexed: 01/12/2023]
Abstract
OBJECTIVE Emergence of chemoresistance in the course of treatments with platinum drugs remains a major hurdle to ovarian carcinoma therapy. We have previously shown that acquisition of cisplatin resistance by OAW42-R ovarian carcinoma cells was associated with the loss of ERK activation in response to cisplatin. To try to sensitize this cell line by restoring ERK activation, we tested a new synthetic compound, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol (2,3-DCPE), which was described to induce ERK activation and to display anticancer properties. METHODS We treated four ovarian carcinoma cell lines with 2,3-DCPE, alone or combined with cisplatin. We characterized its effects on apoptosis induction and proliferation and correlated them with molecular modulations. RESULTS We showed that 2,3-DCPE induced cell death and ERK phosphorylation in a time- and concentration-dependent manner in OAW42-R cells. 2,3-DCPE-triggered apoptosis was also associated with the inhibition of Bcl-2 expression and, to a less extent, with that of Bcl-xL. Treatment with 2,3-DCPE also elicited a strong G0/G1 cell cycle arrest, accompanied with p21WAF1/CIP1 up-regulation. All of these effects revealed to be irreversible. Moreover, 2,3-DCPE exerted a cytostatic effect on OAW42, IGROV1-R10 and SKOV3 ovarian carcinoma cells, the sensitivity to 2,3-DCPE appearing in particular linked with a low basal level of P-ERK. Finally, we showed that 2,3-DCPE increased the cytotoxic effect of cisplatin in OAW42-R resistant cells. CONCLUSION Our results emphasized the potential interest of 2,3-DCPE, used alone or combined with cisplatin, for ovarian carcinoma treatment. The absence of basal P-ERK may constitute a predictive marker of response to this novel therapy.
Collapse
Affiliation(s)
- M Villedieu
- Groupe Régional d'Etudes sur le Cancer (EA 1772, Université de Caen Basse-Normandie), Unité Biologie et Thérapies Innovantes des Cancers Localement Agressifs, Centre de Lutte Contre le Cancer François Baclesse, Caen, France.
| | | | | | | | | | | |
Collapse
|
16
|
Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L, Icard P. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 2006; 26:3561-6. [PMID: 17094483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
BACKGROUND 2-Deoxy-D-glucose (2-DG) is an analog of glucose that is preferentially captured by tumors and is accumulated in transformed cells, because the phosphorylated molecule (2-DG-6P) cannot be metabolized or diffused outside the cells. Targeted with a fluorine atom, 18F-DG is currently used to visualize malignant tumors (PET scan). Although cancer cells have been reported to be strongly dependent on glycolysis (Warburg effect), very few reports have studied the inhibitory effects of 2-DG on cancer. MATERIALS AND METHODS Our objective was to study, in a large panel of human malignant cells of various origins (ovarian, squamous, cerebral, hepatic, colonic and mesothelial), if the inhibitory activity of 2DG against tumor growth could be considered a general phenomenon and to determine its effect on the cell cycle. RESULTS Four types of response in the different cell lines were observed when cells were cultured in the presence of 2-DG (5 mM) continuous exposure: proliferation slow down; proliferation arrest without signs of apoptosis; strong cell cycle arrest accompanied by moderate apoptosis induction; massive apoptosis. CONCLUSION 2-DG appears as an interesting new therapeutic agent against cancer in vitro, and should be tested in in vivo studies.
Collapse
Affiliation(s)
- Xiao Dong Zhang
- Groupe Régional d'Etudes sur le Cancer (Grecan), Unité "Biologie et Thérapies Innovantes des Cancers Localement Agressifs", CLCC François Baclesse, Caen, France.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol 2006; 101:507-19. [PMID: 16387351 DOI: 10.1016/j.ygyno.2005.11.017] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2005] [Revised: 10/03/2005] [Accepted: 11/10/2005] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Recurrence and cisplatin resistance that progressively develops in the course of treatments are major impediments in ovarian cancer therapy. We investigated the involvement of alterations of different signaling pathways in this acquired chemoresistance. METHODS We studied the activation of these pathways in a model of progressive acquisition of resistance that we established, by discontinuously exposing a sensitive ovarian carcinoma cell line, OAW42, to increasing concentrations of cisplatin. RESULTS OAW42-T1 and -T2 variants, which emerged after the first two treatments of OAW42 cells with 5 microg/ml cisplatin, showed enhanced but transient resistance. OAW42-R cells, obtained following successive reiterations of the treatment, displayed both a stronger resistance to cisplatin-induced apoptosis and an increased capacity to recover a normal proliferation after treatment. The measurement of DNA adducts demonstrated that the mechanisms leading to a decreased DNA platination could not explain the level of resistance of OAW42-R cells. The simultaneous study of activation pattern of key proteins of different signaling pathways revealed that cisplatin induced both activation of ERK and p38 and inhibition of P-FAK in the sensitive cells, whereas it progressively failed to elicit such a response in the resistant variants. In contrast, STAT3 and Akt did not seem to be involved in the acquired chemoresistance in our model. CONCLUSIONS Our results suggested that emergence of chemoresistance was accompanied with the progressive loss of ERK and p38 activation and with the maintenance of FAK activation in response to cisplatin, and they demonstrated that these alterations were early events in the course of treatments.
Collapse
Affiliation(s)
- M Villedieu
- Groupe Régional d'Etudes sur le Cancer, (EA 1772, Université de Caen Basse-Normandie), Unité Biologie et Thérapies Innovantes des Cancers Localement Agressifs, CLCC F. Baclesse, Avenue du général Harris, 14076 Caen cedex 05, France
| | | | | | | | | | | |
Collapse
|